Clinical TrialsThe expected release of data from the Phase II ARCHER trial in acute myocarditis could unlock significant value for CRDL.
Market OpportunitiesThe potential market opportunity for CRD-38 is significant, with approximately 1.2 million heart failure hospitalizations in the U.S. each year and no approved drugs targeting inflammatory/fibrotic mechanisms.
Regulatory ProgressCardiolRx has FDA Orphan Drug designation for the treatment of pericarditis, which supports its regulatory pathway to approval.